In the Claims:

Claims 42, 45, 46 and 48-50 are pending in the present application. Claims 45 and 48-50 have been withdrawn from consideration. Claims 42 and 46 are currently under examination. Please amend claim 46, without prejudice, as indicated below. Added text is underlined and deleted text is ~~struck through~~.

Claim 42. (Previously Presented) A method of treating Acquired Immunodeficiency Disease in a patient comprising administering to said patient an effective amount of a combination of an antibody to gamma interferon, an antibody to alpha interferon, and an antibody to tumor necrosis factor-alpha.

Claim 43. (Canceled)

Claim 44. (Canceled)

Claim 45. (Withdrawn) The method of claim 35, wherein said plurality of autoimmune inhibitors further comprises an autoimmune inhibitor selected from the group consisting of at least one of an antibody to an HLA class II antigen, an antibody to an HLA class II antigen receptor and an HLA class II antigen receptor.

Claim 46. (Currently Amended) The method of claim 42, wherein said antibody is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, combinations thereof, and a biologically active ~~fragments~~ fragment, wherein the biologically active fragment is a fragment of an antibody and binds gamma interferon, alpha interferon or tumor necrosis factor alpha ~~and allelelc or species variants thereof~~.

Claim 48. (Withdrawn) The method of claim 33, wherein an effective amount of beta interferon is also administered to the patient.

Claim 49. (Withdrawn) A method of treating Acquired Immunodeficiency Disease in a patient comprising administering to said patient an autoimmune inhibitor selected from the group consisting of an antibody to gamma interferon, an antibody to gamma interferon receptor and a gamma interferon receptor in an amount effective to neutralize or reduce fluid

activity levels of gamma interferon.

Claim 50. (Withdrawn) A method of treating Acquired Immunodeficiency Disease in a patient comprising administering to said patient an autoimmune inhibitor selected from the group consisting of an antibody to an HLA class II antigen, an antibody to an HLA class II antigen receptor and an HLA class II antigen receptor in an amount effective to neutralize or reduce fluid activity levels of said HLA class II antigen.